Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.67) per share which beat the analyst consensus estimate of $(0.70) by 4.29 percent. The company reported quarterly sales of $12.588 million which missed the analyst consensus estimate of $13.248 million by 4.98 percent. This is a 31.84 percent decrease over sales of $18.467 million the same period last year.
Nurix Therapeutics Q3 2024 GAAP EPS $(0.67) Beats $(0.70) Estimate, Sales $12.588M Miss $13.248M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated